The present disclosure relates to a cocrystal of pterostilbene and a coformer capable to form hydrogen bond interactions, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The present disclosure also relates to a composition comprising the cocrystal.

There is provided a process and an apparatus for urea production in which preheating of raw material ammonia or heating in a medium-pressure decomposition step can be performed at a relatively low pressure while preventing decrease in an overall heat transfer coefficient. A process for urea production includes: a synthesis step of generating a urea synthesis solution; a high-pressure decomposition step of heating the urea synthesis solution to separate a gaseous mixture containing ammonia and carbon dioxide from the urea synthesis solution; a condensation step of condensing the gaseous mixture; a medium-low-pressure steam generation step of reducing a pressure of medium-pressure steam condensate obtained in the high-pressure decomposition step to a medium-low pressure to generate medium-low-pressure steam and medium-low-pressure steam condensate; and one or both of a medium-pressure decomposition step and an ammonia preheating step.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The present invention relates to the cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid, a process for obtaining said cocrystals, combination products and pharmaceutical compositions comprising said cocrystals and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by A.sub.1 adenosine receptor antagonism.

The present invention relates to the cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid, a process for obtaining said cocrystals, combination products and pharmaceutical compositions comprising said cocrystals and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by A.sub.1 adenosine receptor antagonism.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

Provided is a method for preparing graphene by liquid-phase ball milling exfoliation, including following steps: mixing a transition metal halide salt, a nitrogen source substance and an organic solvent to prepare an intercalation agent; mixing the intercalation agent with graphite, carrying out ball milling, and then performing centrifugation to obtain a graphite intercalation compound; washing and filtering the graphite intercalation compound obtained, adding an expansion agent, and carrying out ultrasonic agitation to obtain a graphene dispersion; and washing, filtering and drying the graphene dispersion to obtain graphene powder.

The present invention provides crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ, process for the preparation of crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ and its pharmaceutical compositions thereof. The present invention also provides co-crystals of Roxadustat Form RLP, Roxadustat Form RNM and Roxadustat Form RU, process for their preparation and pharmaceutical composition thereof.

The present invention provides crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ, process for the preparation of crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ and its pharmaceutical compositions thereof. The present invention also provides co-crystals of Roxadustat Form RLP, Roxadustat Form RNM and Roxadustat Form RU, process for their preparation and pharmaceutical composition thereof.